You are here

  • Home
  • Archive
  • Volume 29, Issue 4
  • Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease

Article metrics

Article menu
Download PDFPDF
Original research
Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease

 

Online download statistics by month:

Online download statistics by month: October 2020 to March 2024

AbstractFullPdf
Oct 202028538
Nov 20206421314
Dec 20209333
Jan 202121622
Feb 202111412
Mar 202116422
Apr 20218312
May 20215000
Jun 2021200
Jul 2021211
Aug 2021002
Sep 2021220
Oct 202110732
Nov 202124023
Dec 202123820
Jan 202221311
Feb 202216203
Mar 202220710
Apr 202226411
May 202224521
Jun 2022386185
Jul 202258695
Aug 202246641
Sep 202214981
Oct 202211921
Nov 202214193
Dec 20229100
Jan 20238400
Feb 202313021
Mar 20236321
Apr 20233110
May 20235931
Jun 20234112
Jul 20231800
Aug 20233810
Sep 20234411
Oct 20234841
Nov 20238811
Dec 202312911
Jan 20248200
Feb 20244003
Mar 202414323
Total630510978